

June 22, 2022

# Analyst Meet Update

■ Change in Estimates	🔳 Target	Reco
-----------------------	----------	------

#### **Change in Estimates**

	Current		Pre	vious
	FY23E	FY24E	FY23E	FY24E
Rating	E	BUY	I	BUY
Target Price	4	,900	4	,900
Sales (Rs. m)	2,27,660	2,49,382	2,27,660	2,49,382
% Chng.	-	-		
EBITDA (Rs. n	n) 47,427	55,338	47,427	55,338
% Chng.	-	-		
EPS (Rs.)	178.9	212.2	178.9	212.2
% Chng.	-	-		

#### Key Financials - Consolidated

Y/e Mar	FY21	FY22	FY23E	FY24E
Sales (Rs. bn)	190	214	228	249
EBITDA (Rs. bn)	45	46	47	55
Margin (%)	23.6	21.5	20.8	22.2
PAT (Rs. bn)	19	24	30	35
EPS (Rs.)	115.1	141.6	178.9	212.2
Gr. (%)	(1.9)	23.1	26.3	18.7
DPS (Rs.)	28.8	34.5	40.3	46.0
Yield (%)	0.7	0.8	0.9	1.1
RoE (%)	11.6	12.9	14.7	15.5
RoCE (%)	16.7	16.0	15.1	16.7
EV/Sales (x)	3.7	3.3	3.0	2.7
EV/EBITDA (x)	15.8	15.2	14.4	12.1
PE (x)	37.1	30.1	23.9	20.1
P/BV (x)	4.1	3.7	3.3	2.9

Key Data	REDY.BO   DRRD IN
52-W High / Low	Rs.5,615 / Rs.3,654
Sensex / Nifty	52,532 / 15,639
Market Cap	Rs.710bn/ \$ 9,098m
Shares Outstanding	166m
3M Avg. Daily Value	Rs.2189.83m

#### **Shareholding Pattern (%)**

Promoter's	26.72
Foreign	25.16
Domestic Institution	24.34
Public & Others	23.78
Promoter Pledge (Rs bn)	-

#### Stock Performance (%)

	1M	6M	12M
Absolute	0.5	(7.6)	(19.2)
Relative	3.9	(1.0)	(19.1)

#### Param Desai

paramdesai@plindia.com | 91-22-66322259

#### Akshaya Shinde

akshayashinde@plndia.com | 91-22-66322490

# Dr. Reddy's Laboratories (DRRD IN)

### Rating: BUY | CMP: Rs4,269 | TP: Rs4,900

## Multiple growth initiatives

#### **Quick Pointers:**

- Creating new growth avenues like CDMO, Biosimilars, Nutraceuticals and immune –oncology.
- Disciplined capital allocation and productivity enhancement will be the key focus; expect double digit revenue growth with +25% OPM and +25% RoCE.

Dr Reddy's (DRRD) management outlined its strategy to create new (Horizon 2) business models, while growing in existing spaces (Horizon 1) to drive sustainable growth. The company expects double digit revenue growth in the medium term, with aspiration of +25% OPM and 25% RoCE. Horzion 2 will focus on biosimilars, nutraceuticals, Immuno-oncology and new disease management. Most of these initiatives from financials perspective will be visible over next 3-5 years.

Our FY23E/FY24E estimates remain unchanged. We continue to expect steady earnings momentum and pick up in US generic business along with cost optimization. Also, strong pipeline/new launches will drive steady growth in India and RoW markets. We expect 13% EPS CAGR over FY22-24E (ex of Revlimid) and maintain our 'Buy' rating with TP of Rs4,900/share. At CMP, DRRD is trading at 19x P/E on FY24E adjusted for gRevlimid.

- New growth avenues: Company is planning to build its Immuno-oncology in NCEs, Biologics & CGT, Nutraceuticals, CDMO, new disease management and digital services which will start contributing meaningfully from 2027. We believe, investments in these avenues will lead to overall 50-100bps increase of expenses.
- India- aims to be in top 5: India market have grown by 2x in last 4 years. Currently company has 16 brands in IPM in top 300, with 15 brands having +Rs1bn revenues. DRRD aspires to be in top 5 from current rank of 10 with focus on building big brands through strong product management processes. Further multiple initiatives like nutraceuticals, OTC and inorganic route will scale up domestic formulation business.
- US –robust pipeline: DRRD has robust pipeline of 175 products with 90 filed, out of which 40% are injectables/sterile products. Filings for complex products will continue to focus on +25 products across Drug-device combos, peptides and long-acting Injectables. Contribution from US has come down from 50% in FY16 to 37%. In the near term non US markets will continue to grow faster than US generics.
- Other highlights: (1) China- will continue to focus on key markets- It aims to grow 2-3x in next 5 years with double digit filings annually. Currently 17 filings pending for approval. (2) API Aim to backward-integrate 70%+ core molecules which should result in +500 bps gross margin improvement in next 5 years. Geographical diversification will be key focus area. (3) R&D cost to inch up 10-11% of sales from current level of 9%. Investments in biosimilars is around 25-30% of R&D, which will grow faster (4) Expect FTO injectable plant to be inspected in July month. (5) Biosimilar: Currently 12 products in pipeline across various stages of development, filed 1 so far with 2 assets expected to enter clinical phase by FY23. (6) EU will be another important market for DRRD which has already grown by 2x in last 3 years. Segments like Biosimilar, complex generics and other branded generics have huge opportunities in the near future.

# Dr. Reddy's Laboratories

FY22

1,96,955 1,97,172 2,06,062 2,16,768

FY23E

FY24E

FY21

# **Financials**

#### Income Statement (Rs m)

Y/e Mar	FY21	FY22	FY23E	FY24E	Y/e Mar
Net Revenues	1,89,721	2,14,391	2,27,660	2,49,382	Non-Current Assets
YoY gr. (%)	8.7	13.0	6.2	9.5	
Cost of Goods Sold	86,644	1,00,551	1,08,255	1,17,387	Gross Block
Gross Profit	1,03,077	1,13,840	1,19,405	1,31,995	Tangibles
Margin (%)	54.3	53.1	52.4	52.9	Intangibles
Employee Cost	-	-	-	-	
Other Expenses	16,541	17,482	18,706	19,922	Acc: Dep / Amortizati Tangibles
EBITDA	44,773	46,101	47,427	55,338	Intangibles
YoY gr. (%)	9.4	3.0	2.9	16.7	
Margin (%)	23.6	21.5	20.8	22.2	Net fixed assets
					Tangibles
Depreciation and Amortization	12,796	11,824	12,754	13,978	Intangibles
EBIT	31,977	34,277	34,674	41,360	Capital Work In Progre
Margin (%)	16.9	16.0	15.2	16.6	Goodwill
					Non-Current Investmer
Net Interest	(2,635)	(4,880)	(4,200)	(4,700)	Net Deferred tax asset
Other Income	-	-	-	-	Other Non-Current Ass
Profit Before Tax	34,612	39,157	38,874	46,060	Current Assets
Margin (%)	18.2	18.3	17.1	18.5	Investments Inventories
Total Tax	9,175	8,730	9,913	11,745	Trade receivables
Effective tax rate (%)	26.5	22.3	25.5	25.5	Cash & Bank Balance
	20.0	22.0	20.0	20.0	Other Current Assets
Profit after tax	25,437	30,427	28,961	34,314	Total Assets
Minority interest	-	-	-	-	
Share Profit from Associate	480	703	800	1,000	Equity
					Equity Share Capital
Adjusted PAT	19,149	23,568	29,761	35,314	Other Equity
YoY gr. (%)	(1.8)	23.1	26.3	18.7	Total Networth
Margin (%)	10.1	11.0	13.1	14.2	
Extra Ord. Income / (Exp)	-	-	-	-	Non-Current Liabilitie
					Long Term borrowing
Reported PAT	19,149	23,568	29,761	35,314	Provisions
YoY gr. (%)	(1.8)	23.1	26.3	18.7	Other non current liab
Margin (%)	10.1	11.0	13.1	14.2	
					Current Liabilities
Other Comprehensive Income	-	-	-	-	ST Debt / Current of I
Total Comprehensive Income	19,149	23,568	29,761	35,314	Trade payables
Equity Shares O/s (m)	166	166	166	166	Other current liabilitie
EPS (Rs)	115.1	141.6	178.9	212.2	Total Equity & Liabilit

Intangibles Acc: Dep / Amortization Tangibles Intangibles Net fixed assets	57,037 <b>1,04,196</b> 82,807 21,389 <b>92,759</b> 57,111 35,648	43,594 1,07,307 90,959 16,348 89,865	37,483 1,13,950 99,894 14,056 92,111	31,190 <b>1,21,426</b> 1,09,730 11,696
Tangibles Intangibles	82,807 21,389 <b>92,759</b> 57,111	90,959 16,348 <b>89,865</b>	99,894 14,056	1,09,730
Intangibles	21,389 <b>92,759</b> 57,111	16,348 <b>89,865</b>	14,056	
	<b>92,759</b> 57,111	89,865		11,696
Net fixed assets	57,111		92,111	
		60.640	,	95,342
Tangibles	35 648	62,619	68,684	75,849
Intangibles	00,010	27,246	23,427	19,494
Capital Work In Progress	-	-	-	-
Goodwill	4,568	4,418	4,418	4,418
Non-Current Investments	8,333	7,986	12,486	12,486
Net Deferred tax assets	10,292	12,721	12,721	12,721
Other Non-Current Assets	952	948	948	948
Current Assets				
Investments	19,744	29,513	29,513	29,513
Inventories	45,412	50,884	53,753	58,882
Trade receivables	49,641	66,764	66,401	72,736
Cash & Bank Balance	14,829	14,852	16,858	33,878
Other Current Assets	18,623	19,093	20,048	21,050
Total Assets	2,54,861	2,84,323	2,96,536	3,29,254
Equity				
Equity Share Capital	832	832	832	832
Other Equity	1,74,149	1,89,695	2,12,758	2,40,418
Total Networth	1,74,981	1,90,527	2,13,590	2,41,250
Non-Current Liabilities				
Long Term borrowings Provisions	6,299 -	5,746 -	5,746 -	5,746 -
Other non current liabilities	2,401	2,479	2,479	2,479
Current Liabilities				
ST Debt / Current of LT Debt	24,000	28,099	15,000	15,000
Trade payables	21,916	25,572	25,560	27,716
Other current liabilities	35,556	44,621	46,882	49,783
Total Equity & Liabilities	2,54,861	2,84,323	2,96,536	3,29,254

Source: Company Data, PL Research

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

# P

#### Cash Flow (Rs m)

Y/e Mar	FY21	FY22	FY23E	FY24E
PBT	44,773	46,101	47,427	55,338
Add. Depreciation	12,796	11,824	12,754	13,978
Add. Interest	2,635	4,880	4,200	4,700
Less Financial Other Income	-	-	-	-
Add. Other	(10,497)	(16,548)	(16,954)	(18,678)
Op. profit before WC changes	49,707	46,257	47,427	55,338
Net Changes-WC	(8,288)	(10,712)	(761)	(7,410)
Direct tax	(5,716)	(7,437)	(9,913)	(11,745)
Net cash from Op. activities	35,703	28,108	36,753	36,183
Capital expenditures	(25,255)	(14,986)	(19,500)	(17,000)
Interest / Dividend Income	-	-	-	-
Others	-	-	-	-
Net Cash from Invt. activities	(25,255)	(14,986)	(19,500)	(17,000)
Issue of share cap. / premium	-	-	-	-
Debt changes	(7,263)	4,099	(13,099)	-
Dividend paid	(4,147)	(4,146)	(6,698)	(7,654)
Interest paid	2,635	4,880	4,200	4,700
Others	11,103	(17,932)	350	791
Net cash from Fin. activities	2,328	(13,099)	(15,247)	(2,163)
Net change in cash	12,776	23	2,006	17,020
	25,962	13,448	21,753	19,183

#### Quarterly Financials (Rs m)

Y/e Mar	Q1FY22	Q2FY22	Q3FY22	Q4FY22
Net Revenue	49,194	57,632	53,197	54,368
YoY gr. (%)	11.4	17.7	7.9	15.0
Raw Material Expenses	23,495	26,846	24,585	25,625
Gross Profit	25,699	30,786	28,612	28,743
Margin (%)	52.2	53.4	53.8	52.9
EBITDA	9,025	13,357	12,018	11,702
YoY gr. (%)	(18.9)	9.3	6.7	15.1
Margin (%)	18.3	23.2	22.6	21.5
Depreciation / Depletion	2,905	2,985	2,976	2,959
EBIT	6,120	10,372	9,042	8,743
Margin (%)	12.4	18.0	17.0	16.1
Net Interest	(652)	(319)	(289)	(859)
Other Income	487	1,743	240	291
Profit before Tax	7,259	12,434	9,571	9,893
Margin (%)	14.8	21.6	18.0	18.2
Total Tax	1,717	2,761	2,644	1,608
Effective tax rate (%)	23.7	22.2	27.6	16.3
Profit after Tax	5,542	9,673	6,927	8,285
Minority interest	-	-	-	-
Share Profit from Associates	166	247	185	105
Adjusted PAT	5,708	9,920	7,065	875
YoY gr. (%)	(1.5)	30.1	3,468.2	(84.2)
Margin (%)	11.6	17.2	13.3	1.6
Extra Ord. Income / (Exp)	-	-	47	7,515
Reported PAT	5,708	9,920	7,112	8,390
YoY gr. (%)	(1.5)	18.0	15.3	51.2
Margin (%)	11.6	17.2	13.4	15.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	5,708	9,920	7,112	8,390
Avg. Shares O/s (m)	166	166	166	-
EPS (Rs)	34.4	59.8	42.6	5.3

Dr. Reddy's Laboratories

Key Financial Metrics				
Y/e Mar	FY21	FY22	FY23E	FY24E
Per Share(Rs)				
EPS	115.1	141.6	178.9	212.2
CEPS	192.0	212.7	255.5	296.2
BVPS	1,051.6	1,145.0	1,283.6	1,449.8
FCF	156.0	80.8	130.7	115.3
DPS	28.8	34.5	40.3	46.0
Return Ratio(%)				
RoCE	16.7	16.0	15.1	16.7
ROIC	14.5	14.3	13.9	15.6
RoE	11.6	12.9	14.7	15.5
Balance Sheet				
Net Debt : Equity (x)	0.0	(0.1)	(0.1)	(0.2)
Net Working Capital (Days)	141	157	152	152
Valuation(x)				
PER	37.1	30.1	23.9	20.1
P/B	4.1	3.7	3.3	2.9
P/CEPS	22.2	20.1	16.7	14.4
EV/EBITDA	15.8	15.2	14.4	12.1
EV/Sales	3.7	3.3	3.0	2.7
Dividend Yield (%)	0.7	0.8	0.9	1.1

Source: Company Data, PL Research


#### **Key Operating Metrics**

Y/e Mar	FY21	FY22	FY23E	FY24E
India Formulations	33,419	41,957	46,007	51,528
US formulations	70,494	74,915	83,052	89,021
Russia	15,800	20,900	17,030	19,073
PSAI	31,982	30,740	33,199	35,855

Source: Company Data, PL Research

# Dr. Reddy's Laboratories

#### **Price Chart**



Recommend	ation	Historv

No.	Date	Rating	TP (Rs.) Share Prie	ce (Rs.)
1	20-May-22	BUY	4,900	3,929
2	08-Apr-22	BUY	5,200	4,317
3	31-Jan-22	BUY	5,200	4,219
4	07-Jan-22	BUY	5,400	4,708
5	01-Nov-21	BUY	5,400	4,659

#### Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	5,000	3,862
2	Aster DM Healthcare	BUY	234	191
3	Aurobindo Pharma	Accumulate	635	534
4	Cipla	BUY	1,085	926
5	Divi's Laboratories	Accumulate	4,300	3,898
6	Dr. Reddy's Laboratories	BUY	4,900	3,929
7	Eris Lifesciences	BUY	850	670
8	Fortis Healthcare	BUY	330	235
9	Glenmark Pharmaceuticals	Accumulate	450	409
10	HealthCare Global Enterprises	BUY	347	276
11	Indoco Remedies	BUY	430	350
12	Ipca Laboratories	BUY	1,085	938
13	Krishna Institute of Medical Sciences	BUY	1,600	1,250
14	Lupin	Hold	600	635
15	Max Healthcare Institute	BUY	427	355
16	Narayana Hrudayalaya	BUY	773	634
17	Sun Pharmaceutical Industries	BUY	1,020	888
18	Torrent Pharmaceuticals	BUY	3,250	2,635
19	Zydus Lifesciences	BUY	450	357

#### PL's Recommendation Nomenclature (Absolute Performance)

Buy Accumulate Hold Reduce Sell Not Rated (NR)	::	<ul> <li>&gt; 15%</li> <li>5% to 15%</li> <li>+5% to -5%</li> <li>-5% to -15%</li> <li>&lt; -15%</li> <li>No specific call on the stock</li> </ul>
Not Rated (NR) Under Review (UR)		No specific call on the stock Rating likely to change shortly

### **ANALYST CERTIFICATION**

#### (Indian Clients)

We/l, Mr. Param Desai- MBA Finance, Ms. Akshaya Shinde- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

#### DISCLAIMER

#### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Ms. Akshaya Shinde- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

#### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com